By Dean Seal
Salarius Pharmaceuticals said regulators have cleared an investigational drug application to start a clinical trial for its lymphoma treatment SP-3164.
The clinical-stage biopharmaceutical company said the go-ahead from the U.S. Food and Drug Administration allows it to commence a Phase 1 clinical trial of SP-3164 in patients with relapsed or refractory non-Hodgkin lymphoma.
Salarius expects to start treating patients in the dose-escalation portion of the trial in the second half of 2023.
Shares advanced 1.4% to $1.47 in premarket trading Tuesday.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
07-11-23 0903ET